NEW YORK(GenomeWeb) – NanoString on Thursday announced that Medicare contractor Palmetto GBA has issued a favorable final local coverage determination under its MolDx program for the firm's Prosigna breast cancer assay.
Already have a GenomeWeb or 360Dx account?Login Now.
In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.
Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.
The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.
In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.